Once upon a time, he really liked it. Beaten up for inability to bring forward a weight-loss drug; that may or may not be a realistic critique of this stock long term. Analyst community is really...just...waiting. He sold last year, not ready to come back in. Solid company, an improved oncology pipeline might be a reason to get back in.
Thinks dividend is safe, but may be challenged. Spent billions on acquisitions, but hasn't gained much. Not growing. Any boost to bottom line comes from cost cuts. Downhill since Covid, pipeline not strong. Better opportunities in the pharma space, such as MRK.
Failure in a couple of drugs. Huge research program; they will find new drugs. Outstanding stock to accumulate because, at some point, they're going to announce a new drug and the stock will pop. Yield is close to 7-8%.
Hangover from its Covid highs. Working on an obesity pill, but pulled back on it. Opportunities in the pipeline. Owned in his income growth portfolio for the yield. Despite the chart, likes it here. Fairly cheap, hopefully hitting a bottom (knock wood).
She likes the space but people are not investing in it. It has a low valuation and is tempting but she prefers elsewhere. It is a global leader in a crowded field. She sees 5% growth so there is some upside.
The problem with pharma is that their drugs all face a patent cliff. Over the last 25 years, pharma companies have tried to sustain themselves through consolidation (mergers, buying small companies). Caution: the dividend may look attractive, but that could be the result of the falling share price.
Once upon a time, he really liked it. Beaten up for inability to bring forward a weight-loss drug; that may or may not be a realistic critique of this stock long term. Analyst community is really...just...waiting. He sold last year, not ready to come back in. Solid company, an improved oncology pipeline might be a reason to get back in.